Novartis’ Multiple Sclerosis Brands Mayzent and Kesimpta Both Show Strong Growth in Canada According to Surveyed Neurologists in Spherix Report

Despite a negative CDEC1 reimbursement recommendation, BMS’ Zeposia has seen notable growth in the past six months, with neurologists optimistic about the future EXTON, Pa., May 26, 2022 /PRNewswire/ — Following an eventful 2021 that included the launch of two new brands—Novartis’…

Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*